R/R Follicular Lymphoma: Testing for EZH2

Video

Andrew M. Evens, DO, MSc, FACP, of Rutgers Cancer Institute of New Jersey, comments on the rationale for testing for EZH2 mutations in relapsed/refractory follicular lymphoma.

Ian Flinn, MD, PhD: Andy, you talked about the FDA indication for tazemetostat and whether you’re mutant. A lot of practical questions about testing for EZH2 come up. One, does it matter? Krish just gave an argument by describing that results are pretty good whether you are mutant or not. But if you want to test somebody for the mutation, does it matter what sample you’re using? Does it matter whether it’s the initial biopsy? Does it matter whether it’s in the relapsed setting? How are you doing this, or are you doing it? Do you bother?

Andrew M. Evens, DO, MSc, FACP: Yeah, we are. Maybe I’m standing on an academic soapbox, where you just like having more information and you like to have that mutational data. But you are right. It’s approved, for the record, even though it’s a wordy approval, regardless of mutation status. I try to look at it in terms of, how does it help you? Even though, yes, the PFS [progression-free survival] or duration of response is similar, between 70% and 30% is a big difference. How I’m thinking about it is, if someone is mutated, that probably follows right behind R2 [rituximab, lenalidomide] therapy for me. In many instances, ahead of PI3 kinase, etc. Whereas if I know it’s not, and I’m confident on that test, I might place it behind PI3 kinase inhibition. Now, I’m not saying it’s number to number. You have to look at other factors, interactions, and toxicities.

In terms of the question of what sample to test it on, at least in talking through guidance with the company and other colleagues who are experts in EZH2, it sounds as if it’s a pretty stable mutation. You are able to test it on archival specimens. So yes, you could do it on a fresh specimen or you could do it on an archival specimen.

Ian Flinn, MD, PhD: That’s my understanding as well. From looking at the data, it appears that it’s a very early event that occurs in the clone and maybe there’s a subclone that comes up that changes the expression. But even in patients who have transformed follicular lymphoma to large B-cell lymphoma, they often maintain that EZH2 mutation.

Transcript Edited for Clarity

Related Videos
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Lori A. Leslie, MD
Changchun Deng, MD, PhD
Guenther Koehne, MD, PhD
Ibrahim Aldoss, MD
Andrew P. Jallouk, BS, MD, PhD, assistant professor, Vanderbilt University
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Ibrahim Aldoss, MD
Kateryna Fedorov, MD, assistant professor, hematology-oncology, Vanderbilt University Medical Center
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Related Content
Sattva S. Neelapu, MD

CAR T-Cell Agents Offer Efficacy in Lymphoma, But Additional Approaches Are Needed to Overcome Resistance

May 17th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
OncLive On Air Podcast Recap

Revisit Every OncLive On Air Episode From April 2024

May 13th 2024
Article
Matthew Lunning, DO, FACP

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

December 21st 2023
Podcast
Izidore Lossos, MD, of Sylvester Comprehensive Cancer Center

Loncastuximab Tesirine Elicits Responses in R/R Marginal Zone Lymphoma

May 7th 2024
Article
Harout Semerjian, CEO of GlycoMimetics

Uproleselan Plus Chemotherapy Misses OS End Point in R/R AML

May 6th 2024
Article